TREATMENT RELEASED BY CIPLA ARE A GENERIC VERSION OF THE DRUG MAKER GILEAD SCIENCES INC - HARVONI TABLETS. Cipla said that Hepcvir-L is the first once-a-day, fixed dose oral combination therapy that has been approved for chronic hepatitis C genotype 1 patients. The drug cost price around Twenty Five Thousand (25000) for a bottle of 28 tablets. Hepatitis C is an infectious disease affecting primarily the liver, caused by the HEPATITIS-C virus (HCV).The infection is often asymptomatic, but chronic infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally known after many years. In some cases, those with cirrhosis will go on to develop liver failure, liver cancer, or life-threatening esophageal and gastric varices.
This is custom tab. You can add custom tab as an attribute for entire products, or for each categories. You can add CMS content such as sizing guide or videos to enhance product detail.